Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.39 |
| ▸ | NQO2 | P16083 | 5/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14508402 | 0.93 | CYP11B1 (0.43) | HSD17B1CYP3A4GAACYP2C19MTNR1A | |
| SCHEMBL5481729 | 0.82 | PPARD (0.46) | PPARD | |
| SCHEMBL13424132 | 0.81 | MTNR1A (0.55) | PPARDHSD17B1MTNR1ANQO2MTNR1B | |
| SCHEMBL1470331 | 0.79 | MTNR1A (0.60) | MTNR1ANQO2MTNR1B | |
| SCHEMBL5861977 | 0.78 | NQO2 (0.43) | PPARDHSD17B1MTNR1ANQO2MTNR1B | |
| SCHEMBL1472802 | 0.78 | PPARD (0.46) | PPARD | |
| SCHEMBL19984873 | 0.77 | CYP11B1 (0.55) | PPARDHSD17B1MTNR1ANQO2MTNR1B | |
| SCHEMBL30618514 | 0.77 | CYP1A2 (0.47) | PPARDHSD17B1MTNR1AMTNR1BCYP11B1 | |
| SCHEMBL3348647 | 0.77 | CYP1A2 (0.47) | PPARDHSD17B1MTNR1AMTNR1BCYP11B1 | |
| SCHEMBL14508405 | 0.77 | CA1 (0.41) | CYP3A4GAACYP2C19ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117860-A1 | Bicyclic indolinesulphonamide derivatives | BAYER HEALTHCARE AG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117860-A1 | Bicyclic indolinesulphonamide derivatives | BAYER HEALTHCARE AG (DE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117860-A1 | Bicyclic indolinesulphonamide derivatives | PPARD, PPARA, PPARG | PPARD 1/4885HSD17B1 287/4885CYP3A4 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.